
|Articles|May 18, 2023
How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer
Author(s)Chris Spivey
Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.
Advertisement
Chris Spivey, editorial director, speaks with Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer. In this interview, True shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry, including changes to the "just-in-time" supply chain, pandemic preparedness, and more.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FAQ: What You Need to Know About Agentic AI in Drug Discovery
2
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
5




